Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 6/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12237060 | 0.84 | ALDH1A1 (0.44) | IDO1CYP3A4 | |
| SCHEMBL12237059 | 0.84 | HCRTR2 (0.42) | HCRTR1HCRTR2IDO1CYP3A4AR | |
| SCHEMBL14546379 | 0.84 | IDO1 (0.41) | HCRTR1HCRTR2IDO1CYP3A4AR | |
| SCHEMBL10058161 | 0.83 | HTR1A (0.41) | CYP3A4 | |
| SCHEMBL10058159 | 0.82 | IDO1 (0.41) | IDO1CYP3A4 | |
| SCHEMBL10058625 | 0.81 | RAB9A (0.44) | KDM1A | |
| SCHEMBL13627669 | 0.80 | MEN1 (0.42) | HCRTR1HCRTR2 | |
| SCHEMBL10058619 | 0.79 | HCRTR2 (0.43) | HCRTR1HCRTR2 | |
| SCHEMBL10058064 | 0.76 | METAP2 (0.35) | — | |
| SCHEMBL12237054 | 0.76 | HCRTR2 (0.39) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291902-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291902-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | HCRTR1 4390/4885HCRTR2 4803/4885IDO1 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.